Grants for Special district governments - Food and Nutrition

This funding opportunity supports independent research projects in health-related fields for a wide range of eligible applicants, including universities, nonprofits, and small businesses, without allowing clinical trials.

This funding opportunity supports institutions in creating collaborative training networks for early-career researchers focused on advancing studies in kidney, urologic, and hematologic diseases.

This funding opportunity provides substantial financial support to higher education institutions and nonprofit organizations to establish collaborative centers that advance research and resources for HIV/AIDS.

The Intentional Development Group is proud to announce The Small Business Boost Grant, a program designed to empower local entrepreneurs and strengthen the City of Youngstown’s economic landscape. Donor Name: Department of Agriculture and Markets State: New York County: All Counties Type of Grant: Program Deadline: 06/24/2024 Size of the Grant: More than $1 million Grant Duration: Grant Duration Not Mentioned Details: The Small Business Boost Program, managed by The Intentional Development Group with funds provided by the City of Youngstown, will help boost the economic impact of Small Businesses within the City of Youngstown. Funds are available for projects that mitigate the impact of agriculture on climate change and enhance the on-farm adaptation and resiliency to projected climate conditions. Applications must be for ONE of the following: Track 1A: Livestock Management: Alternative Waste Management and Precision Feed Management; Track 1B: Cover and Flare Projects Track 2: Adaptation and Resiliency; Track 3A: Healthy Soils NY (Systems and BMPs that support soil health and agroforestry); Track 3B: Soil Health Systems; OR Track 4: Agricultural Forest Management. Funding Information Total Available Funding: $28,750,000 Track 1A: Livestock Management: Alternative Waste Management & Precision Feed Management: $4,500,000 State Funds Track 1B: Cover and Flare Projects $7,000,000 Federal Funds Track 2: Adaptation & Resiliency $5,000,000 State Funds Track 3A: Healthy Soils NY (Systems & BMPs that support soil health and agroforestry: $4,500,000 State Funds Track 3B: Soil Health Systems: $7,000,000 Federal Funds Track 4: Agricultural Forestry Management (carbon sequestration): $750,000 State Funds. Eligibility Requirements  Proposals for funding will be accepted from NYS Soil and Water Conservation Districts (Districts). Proposals may be for multiple projects and/or on multiple farm operations but must be for one Track only. Districts may submit more than one application, including separate applications for multiple Tracks on the same farm operation. For more information, visit Department of Agriculture and Markets.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.

This Notice of Funding Opportunity (NOFO) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

The Community Foundation of Southern Wisconsin is currently accepting applications for its Women’s Fund. Donor Name: Community Foundation of Southern Wisconsin State: Wisconsin County: Rock County (WI) Type of Grant: Grant Deadline: (mm/dd/yyyy) 09/15/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: The Women’s Fund is a component of the Community Foundation. The Advisory Board is comprised of community volunteers and Community Foundation staff. The Advisory Board raises money for the endowment as well as recommends grants from the Women’s Fund in support of priorities they set related to the current needs of women and girls in Rock County Wisconsin. Investing in girls yields even higher returns in terms of the effect on women’s wages, the decisions better educated women make about having children, and their capacity to raise healthy, educated children who go on to make good wages, choose smaller family size and invest in their own children. Mission of the fund: To provide a permanently endowed funding source to non-profit agencies serving the needs of women and girls in Rock County. To provide hands-on grant-making and leadership experiences through volunteer opportunities for Fund donors. Eligibility Criteria Seeking proposals from 501(c)(3) charitable Rock County organizations and municipalities offering projects or programs that serve the mental health needs of women and girls. Services and programs eligible for grant funding may include but are not limited to depression, anxiety, caregiver stress, addictions, work/family stress, isolation, and human trafficking. Both prevention and/or response programs are eligible. Training programs for targeted audiences, support groups, mentoring programs, resource identification, and other related programs are examples for possible grant support. Collaborations throughout Rock County are encouraged.Requests from individuals are not eligible. For more information, visit CFSW.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established. This grant will support the continued advancement of FDA;apos;s initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This funding opportunity supports researchers in planning high-risk, multi-center clinical studies focused on kidney, digestive, diabetes, and metabolic disorders, helping them develop essential protocols and administrative frameworks before conducting the actual trials.

This funding opportunity provides financial support for researchers developing innovative, non-opioid treatments for various types of pain, with a focus on early-stage studies and collaboration with underrepresented populations.

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

The GOODS Program is a grant opportunity provided by Greater Good Charities. It aims to distribute food, essential supplies, clothing, housewares, toys, and more to pets and people in need across the world. The program helps various constituents including pets (homeless and owned), families facing economic hardships, unhoused populations, military veterans, domestic violence survivors, victims of disasters, and displaced persons. The GOODS Program works by sourcing and managing excess, re-branded, and short-dated food and supplies from donors such as manufacturers, distributors, and retailers. These products are then made available to qualified distribution groups called Ambassadors who ensure they reach the organizations in need known as Recipients. The program operates through a sustainable hub and spoke model similar to a food bank where goods are donated but costs are covered by handling fees and donations. To apply as a Recipient organization, interested parties can locate the nearest Ambassador on the program's website and apply directly through their website. For general inquiries or to inquire about grants and services, individuals can contact Greater Good Charities through their website or send checks to their designated address in Seattle, WA.

This funding opportunity supports predoctoral students in dual-degree programs at institutions without NIH-funded training programs, helping them pursue research and clinical training to become future physician-scientists.

This funding opportunity supports the development of innovative tools and technologies aimed at advancing research and treatment in kidney, urologic, and hematologic diseases, encouraging projects that push scientific boundaries and have broad applications beyond individual research interests.

The Resilient Food Systems Infrastructure (RFSI) program, funded by the USDA, allocates approximately $2 million for infrastructure grants to Vermont businesses and organizations aiming to strengthen local and regional food systems. The grants support projects that improve the aggregation, distribution, manufacturing, processing, storing, transporting, and wholesaling of Vermont food products. This track encourages development of Vermont value-added products and promotes fair wages and job creation. A 50% match is required, which can be reduced to 25% for historically underserved farmers. Grants range from $100,000 to $500,000 and are available from fall 2024 through February 2027.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.